coronary artery disease
Bayer’s Gadavist becomes first FDA-approved drug for MRI in coronary artery disease patients
July 16, 2019Manufacturing and Production, Sales and Marketing Bayer, FDA, Gadavist, coronary artery disease, pharma
The FDA has awarded approval to Bayer’s Gadavist (gadobutrol) injection, the company confirmed.
FDA says benefits outweigh risks in Abbott’s heart stent, Absorb
March 16, 2016Research and Development, Sales and Marketing Abbott, absorb, bioresorbable, coronary artery disease
An independent panel convened by the US Food and Drug Administration (FDA) has unanimously voted that the benefits of Absorb, …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
